COMMUNIQUÉS West-GlobeNewswire

RESTEM to Present Company Overview in Biotech Showcase 2026
22/12/2025
MIAMI, Dec. 22, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its [...]
CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors
22/12/2025
HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc. , a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of solid tumor cancer, today announced the [...]
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
22/12/2025
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned [...]
Vivos Inc Summarzes Preogress in its Animal Therapy Division
22/12/2025
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported an 800% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary [...]
Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
22/12/2025
Patient achieved complete remission and well-tolerated safety profile, advancing path to Phase 2 BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next- [...]
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
22/12/2025
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, [...]
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
22/12/2025
Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- [...]
OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting 2025
22/12/2025
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator and provider of one of the world's largest regulatory-grade, AI-ready Real-World [...]
Omada Health to Participate in J.P. Morgan Healthcare Conference
22/12/2025
SAN FRANCISCO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 44th Annual J.P. [...]
PeopleOne Health Selected by Orlando Regional REALTOR® Association to Deliver First-of-Its-Kind Healthcare Solution for Realtors
22/12/2025
Partnership to expand access to personalized primary care, including same-day appointments and mental health services, for more than 18,000 Central Florida real estate professionals ORLANDO, Fla., Dec. 22, 2025 (GLOBE [...]
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
22/12/2025
Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive [...]
Wholeview Wellness Joins the Lumina Therapy Alliance, Expanding Access to In-Person Addiction-Focused Psychotherapy for Employees and Their Families
22/12/2025
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lumina Therapy Alliance , the nation’s leading collective of highly vetted, in-person mental health practices, is proud to announce that Wholeview Wellness , the boutique, out [...]
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
22/12/2025
STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer
22/12/2025
Study at the University of Colorado Anschutz Cancer Center builds on preclinical data showing that cirtuvivint plus PARP inhibition overcame resistance in preclinical models of high‑grade serous ovarian cancer SAN DIEGO [...]
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
22/12/2025
Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically developed systemic [...]
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
22/12/2025
HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions [...]
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
22/12/2025
Results Underscore PRP Candidacy as a Disruptor of the Tumor Microenvironment MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
22/12/2025
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, [...]

Pages